Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104014 | 0.81 | MAOB (0.58) | MAOBMAOARAB9ACA12CA1 | |
| SCHEMBL2877136 | 0.81 | MAOB (0.58) | LMNAMAOBMAOARAB9ABCHE | |
| SCHEMBL10874898 | 0.81 | NPC1 (0.58) | MAOBGAAMAOARAB9ACA12 | |
| Benzylphenylether SCHEMBL61660 | 0.80 | LMNA (0.74) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL339813 | 0.80 | LMNA (0.82) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL13105483 | 0.80 | MAOB (0.60) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL5179465 | 0.79 | GPR84 (0.53) | LMNACYP1A2PTGS1SLC6A2CYP2C19 | |
| SCHEMBL18154523 | 0.79 | APP (0.61) | MAOBMAPTRAB9ASMN1; SMN2BCHE | |
| SCHEMBL17979335 | 0.79 | KCNA3 (0.56) | HDAC6MAPTRAB9APARP10LTA4H | |
| SCHEMBL17810144 | 0.79 | MAOB (0.62) | MAOBMAOANR4A2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185595-A1 | AQUEOUS FORMULATIONS FOR REMOVING METAL HARD MASK AND POST-ETCH RESIDUE WITH Cu/W COMPATIBILITY | TRUIST BANK, AS NOTES COLLATERAL AGENT | 2016-06-30 | — | — | US | claimed |
| EP-3027709-A1 | AQUEOUS FORMULATIONS FOR REMOVING METAL HARD MASK AND POST-ETCH RESIDUE WITH Cu/W COMPATIBILITY | Advanced Technology Materials, Inc. (US) | 2016-06-08 | — | — | EP | claimed |
| US-9287052-B2 | Additives for dye-sensitized solar cells | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | claimed |
| WO-2015017659-A1 | AQUEOUS FORMULATIONS FOR REMOVING METAL HARD MASK AND POST-ETCH RESIDUE WITH Cu/W COMPATIBILITY | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2015-02-05 | — | — | WO | claimed |
| US-20130292601-A1 | Additives for Dye-Sensitized Solar Cells | MERCK PATENT GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| CN-102060758-B | Preparation method of 4-benzyloxy-pyridine-2-ketone | UNIV HANGZHOU NORMAL | 2012-12-05 | — | — | CN | claimed |
| CN-102060758-A | Preparation method of 4-benzyloxy-pyridine-2-ketone | UNIV HANGZHOU NORMAL | 2011-05-18 | — | — | CN | claimed |
| CN-116096837-B | Nitride etchant composition and method | 恩特格里斯公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250019590-A1 | NITRIDE ETCHANT COMPOSITION AND METHOD | ENTEGRIS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-12152187-B2 | Nitride etchant composition and method | ENTEGRIS, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4267137-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | Enliven Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4196546-A1 | NITRIDE ETCHANT COMPOSITION AND METHOD | Entegris, Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| EP-1529052-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-05-11 | — | — | EP | disclosed |
| WO-2005007665-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-11-18 | — | — | US | disclosed |
| US-20040116690-A1 | Lincomycin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004016632-A2 | LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-0576622-A1 | LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK COMPANY (US) | 1994-01-05 | — | — | EP | disclosed |
| WO-1992017821-A1 | LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK COMPANY (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230046-A1 | Lincomycin derivatives possessing antibacterial activity | NRDC, NISCH, CLSPN | LMNA 873/4885CYP1A2 3642/4885PTGS1 2453/4885 |
| US-20240116921-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ERBB2, FGFR2, ERBB3 | LMNA 4739/4885CYP1A2 554/4885PTGS1 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.